Royalty Pharma’s updated fair value price target now sits at US$51.56, compared with the previous US$51.00 level. Analysts linking this shift to current Street commentary point to optimism around the ...
Diversified Royalty (DIV:CA) offers bond-like, counter-cyclical royalties; de-risking boosts stability and payout safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results